Also trades as: 0QCV.IL (IOB) · $vol 4M · 0QCV.L (LSE) · $vol 4M · 4AB.DE (XETRA) · $vol 0M · ABBV.TO (TSX) · $vol 0M · ABBV.BA (BUE) · $vol 0M · 4AB.DU (DUS) · $vol 0M
ABBV NYSE
AbbVie Inc.
1W: -0.9%
1M: +7.6%
3M: +8.8%
YTD: +25.9%
1Y: +25.6%
3Y: +110.1%
5Y: +209.1%
$286.44
-0.30 (-0.10%)
Weekly Expected Move ±3.1%
$268
$277
$286
$295
$304
Credit Risk of going bust: lower than 84% of companies Debt: 12.3% of company value Bonds: $2.06B held by 633 funds, 61 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $2.59 (down 99.1%), AbbVie Inc. would be worth roughly what it owes.
Total debt $70.82B against a stock market value of $506.17B.
Distance to default 11.00 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $39.58B (short-term plus half of long-term), stock volatility 25.7%; Altman Z 2.71. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $2.59 (down 99.1%), AbbVie Inc. would be worth roughly what it owes.
Total debt $70.82B against a stock market value of $506.17B.
Distance to default 11.00 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $39.58B (short-term plus half of long-term), stock volatility 25.7%; Altman Z 2.71. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships0
As Filer
counterparties named
8
As Counterparty
mentioned by others
2021-07-27
Earliest Filing
2025-08-07
Latest Filing
Mentioned As Counterparty
8 mentionsOther companies that named ABBV in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| RGNX REGENXBIO Inc. | partner | Parent company of AbbVie Global Enterprises Ltd. | 2025-08-07 | View |
| XLO Xilio Therapeutics, Inc. | investor | Purchased common stock in a private placement and entered into an investor rights agreement | 2025-02-12 | View |
| ALDX Aldeyra Therapeutics, Inc. | partner | Partner in an Exclusive Option Agreement amended by an Extension Side Letter regarding launch activities and expense rei | 2024-11-18 | View |
| ALDX Aldeyra Therapeutics, Inc. | partner | Entered into an exclusive option agreement for co-development and co-commercialization of reproxalap in the US and licen | 2023-11-01 | View |
| ENTA ENANTA PHARMACEUTICALS INC | partner | Holds existing license agreement with Enanta for protease inhibitors | 2023-04-27 | View |
| IMNM Immunome Inc. | partner | Collaboration and option agreement for target discovery and commercialization | 2023-01-06 | View |
| RGNX REGENXBIO Inc. | partner | Parent company of AbbVie Global Enterprises Ltd.; joint press release issuer | 2021-09-13 | View |
| AMGN AMGEN INC | partner | Acquired TeneoOne, Inc., an affiliate of Teneobio. | 2021-07-27 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-15 | Officer/Director Change | View | |
| 2026-10-05 | Earnings Release; Exhibits | View | |
| 2026-09-03 | Regulation FD; Exhibits | View | |
| 2026-08-18 | Other Events; Exhibits | View | |
| 2026-08-05 | Other Events; Exhibits | View | |
| 2026-07-31 | Earnings Release; Exhibits | View | |
| 2026-07-06 | Earnings Release; Exhibits | View | |
| 2026-06-22 | Regulation FD; Exhibits | View | |
| 2026-05-12 | Shareholder Vote | View | |
| 2026-04-29 | Earnings Release; Exhibits | View | |
| 2026-04-03 | Earnings Release; Exhibits | View | |
| 2026-03-04 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-26 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-07-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR